Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Regulation of B cell function by the immunosuppressive agent leflunomide.
Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.
Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
Ampyra (dalfampridine)
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Functional Characterization of DNA Methylation in the Oligodendrocyte Lineage.
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
Combined structural and functional patterns discriminating upper limb motor disability in multiple sclerosis using multivariate approaches.
Benzothiazole and stilbene derivatives as promising PET myelin radiotracers for multiple sclerosis.
Our Products (page shows "Copaxone" as a trade name for glatiramer acetate)
A randomized controlled phase II trial of riluzole in early multiple sclerosis.
Treatment satisfaction in multiple sclerosis.
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis.
Multiple sclerosis in pregnancy.
Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.
Prediction of oxygen uptake during walking in ambulatory persons with multiple sclerosis.
Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b.
The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.
SigmaPharm Laboratories Products
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis.

Pages